Assessment of the Anticoagulation Activity of Apixaban – Reply –

Authors :: Johanne Silvain
Institut de cardiologie [CHU Pitié-Salpêtrière]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Université Pierre et Marie Curie - Paris 6 (UPMC)
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Source :: Circulation Journal, Circulation Journal, Japanese Circulation Society, 2015, 79 (7), pp.1642-1642. ⟨10.1253/circj.CJ-15-0487⟩, Circulation Journal, 2015, 79 (7), pp.1642-1642. ⟨10.1253/circj.CJ-15-0487⟩
Publication Year :: 2015
Publisher :: Japanese Circulation Society, 2015.
Abstract: ACTION Study Group; International audience; We thank Dr Gonçalves and Dr Araújo for their comments. We agree on several points that emphasize the messages that are delivered in our editorial. [...]

Subjects :: Hemostasis
medicine.medical_specialty
Factor VIII
business.industry
General Medicine
Blood Coagulation Factors
Rivaroxaban
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Humans
Medicine
Apixaban
Anticoagulation Activity
Cardiology and Cardiovascular Medicine
business
Intensive care medicine
Factor VIIIa
medicine.drug

Tools